Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...

Aries Wealth Management has tiptoed into biotech by acquiring 605 shares of Vertex Pharmaceuticals, valued around $293,000. Other hedge funds also took notice, adjusting their positions during the ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CCM Investment Advisers gave Vertex Pharmaceuticals a vitamin shot by upping its stake 24.1% in Q1. They purchased an ...

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.